Abstract
Antipsychotic-induced tardive dyskinesia is a potentially irremediable and debilitating condition with the onset most commonly associated with the use of first-generation antipsychotics. The development of tardive dyskinesia on clozapine, a second-generation antipsychotic, is uncommon, and the drug is therefore a treatment option for those patients who develop the syndrome following treatment with first- generation agents. I report on the case of a 27-year-old man who developed severe tardive dyskinesia following initiation of clozapine treatment. To the best of my knowledge, this is the first case of tardive dyskinesia associated with clozapine use reported in South Africa.
Highlights
Antipsychotic-induced tardive dyskinesia is a potentially irremediable and debilitating condition with the onset most commonly associated with the use of first-generation antipsychotics.[1]
The abnormal limb movements improved after discontinuation of clozapine but he remained distressed by the ongoing orofacial dyskinesia
The clinical benefits of the use of SGAs in patients with tardive dyskinesia appear to be twofold. They may ameliorate the symptoms of pre-existing tardive dyskinesia, and are less likely to induce tardive dyskinesia
Summary
L Asmal, MB ChB, FCPsych Department of Psychiatry, Stellenbosch University and University of Cape Town. Antipsychotic-induced tardive dyskinesia is a potentially irremediable and debilitating condition with the onset most commonly associated with the use of first-generation antipsychotics.[1] The development of tardive dyskinesia on clozapine, a second-generation antipsychotic, is uncommon, and the drug is a treatment option for those patients who develop the syndrome following treatment with firstgeneration agents. I report on the case of a 27-year-old man who developed severe tardive dyskinesia following initiation of clozapine treatment. To the best of my knowledge, this is the first case of tardive dyskinesia associated with clozapine use reported in South Africa
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
